Home Apoptosis Bcl-6

Bcl-6

Apoptosis

DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR Carbonic Anhydrase Hydroxylase Liver X Receptor FAAH Acyltransferase Dehydrogenase Phosphorylase PPAR CYP17 CETP FXR HMG-CoA Reductase Transferase IDO/TDO Retinoid Receptor Casein Kinase NAMPT phosphatase Lipase Lipoxygenase Thioredoxin Decarboxylase Vitamin Serine/threonin kinase LDL Fatty Acid Synthase FOX Glycogen synthesis PKM Glycolysis HDL Carbohydrate Metabolism ATP-citrate lyase Acetyl-CoA carboxylase CYP450 PCSK9 Leukotriene PDHK PGC-1α ROR FABP Peroxidases Aldose Reductase Xanthine Oxidase THR Epoxide Hydrolase PEP GTPCH FAO PAI-1 LDH SCD PREP CPSase Mannosidase Thioredoxin Reductase SGK FTase γGCS CPT SREBP Mitochondrial Metabolism PARG Glucosylceramide Synthase Catalase 3-MST Serine hydrolase CAR glucocerebrosidase Mitochondrial pyruvate carrier GOT SHIP SOD LCN Endogenous Metabolite NMT Aconitase AGEs Amino Acids and Derivatives Amylase Drug Metabolite Glucokinase Glucosidase glycosidase GSNOR GST Hexokinase Isocitrate Dehydrogenase (IDH) Lipid Liposome LPL Receptor MAGL NEDD4-1 NPC1L1 PGK1 Reductase stilbene oxidase UGT
  • All (4)
  • Bcl-6 Inhibitors (4)
  • New Bcl-6 Products
Cat.No. Product Name Information Product Use Citations Product Validations
S8591 FX1 FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. This compound shows great selectivity against a panel of 50 different kinases. 10 μM of this chemical fails to significantly inhibit of any of these kinases. It induces apoptosis.
Front Immunol, 2025, 16:1558845
Victoria University of Wellington, 2023,
Haematologica, 2022, 10.3324/haematol.2022.280879
S8250 79-6 (CID5721353) 79-6 (CID5721353), a BCL6 inhibitor, has a Kd value of 138 μM.
Cell Rep Med, 2022, 3(9):100744
S8735 BI-3812 BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
Haematologica, 2022, 10.3324/haematol.2022.280879
bioRxiv, 2022, 10.1101/2022.11.03.514941
S6937 BI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. This compound inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. It exhibits antitumor activity.
Adv Sci (Weinh), 2025, 12(31):e01284
Phytomedicine, 2024, 133:155944
Haematologica, 2022, 10.3324/haematol.2022.280879
S8591 FX1 FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. This compound shows great selectivity against a panel of 50 different kinases. 10 μM of this chemical fails to significantly inhibit of any of these kinases. It induces apoptosis.
Front Immunol, 2025, 16:1558845
Victoria University of Wellington, 2023,
Haematologica, 2022, 10.3324/haematol.2022.280879
S8250 79-6 (CID5721353) 79-6 (CID5721353), a BCL6 inhibitor, has a Kd value of 138 μM.
Cell Rep Med, 2022, 3(9):100744
S8735 BI-3812 BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
Haematologica, 2022, 10.3324/haematol.2022.280879
bioRxiv, 2022, 10.1101/2022.11.03.514941
S6937 BI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. This compound inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. It exhibits antitumor activity.
Adv Sci (Weinh), 2025, 12(31):e01284
Phytomedicine, 2024, 133:155944
Haematologica, 2022, 10.3324/haematol.2022.280879